Abstract:Objective. The aim of this study was to evaluate the effects of a modified Xiaohua Funing decoction (Xfd) on acute liver failure (ALF) and determine whether the protective mechanisms are related to alterations in the gut microbiota. Methods. An animal model of ALF was induced by intraperitoneal injection of D-galactosamine (D-Gal, 0.5 g/kg) and lipopolysaccharide (LPS, 100 μg/kg). Male BALB/c mice were randomly divided into the following 4 groups: the control group (saline, Con), model group (D-Gal/LPS, Mod), silymarin pretreatment group (200 mg/kg, Sil), and modified Xfd pretreatment group (650 mg/kg, Xfd). The Sil and Xfd groups received the respective intervention orally for 14 days and 2 h before D-Gal/LPS treatment. The liver injury markers included alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and liver histology. 16S rRNA gene sequencing was performed to assess the effects on the caecum content. Results. D-Gal/LPS treatment caused severe ALF, illustrating that the ALF model was successfully established. The administration of Sil and Xfd greatly reduced the serum ALT and AST levels and improved the pathological signs of liver injury. However, no significant difference was found between the two groups. In contrast to the Mod group, the Sil and Xfd groups showed a shift toward the Con group in terms of the gut microbiota structure. The abundances of Firmicutes and Bacteroidetes and the Bacteroidetes/Firmicutes ratio in the Mod group significantly differed from those in the Con group. The Sil and Xfd groups showed restoration of the disordered microbiota. Significantly increased relative abundances of Lachnospiraceae_NK4A136_group and Candidatus_Saccharimonas and a markedly decreased Muribaculaceae abundance were found in the Sil and Xfd mice compared with those in the Mod mice ( P < 0.01 , P < 0.05 ). Interestingly, a negative correlation was observed between the abundances of the gut microbiota constituents, specifically Clostridia_UCG-014, and ALT and AST levels. Conclusion. In summary, our results indicate that Xfd may protect the liver and modify the gut microbiota in ALF mice.

Optimization of mouse model of fulminant hepatic failure by factorial experiment

Inhibiting the expression of hepatocyte nuclear factor 4 alpha attenuates lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice.

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

A Novel Scoring System for Prognostic Prediction in D-Galactosamine/lipopolysaccharide-induced Fulminant Hepatic Failure BALB/c Mice

Dynamic metabonomic analysis of BALB/c mice with different outcomes after D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure.

[Establishment of a D-galactosamine/lipopolysaccharide Induced Acute-on-chronic Liver Failure Model in Rats].

Establishment and further improvement of D-galactosamine induced acute hepatic failure in Duroc breeding pigs

Metabolic Profiling Analysis of a<scp>d</scp>-Galactosamine/Lipopolysaccharide-Induced Mouse Model of Fulminant Hepatic Failure

Dynamic Variability of Intestinal Flora and Endotoxin in Rat with Fulminate Hepatic Failure

Enhanced expressions and activations of leukotriene C4 synthesis enzymes in D-galactosamine/lipopolysaccharide-induced rat fulminant hepatic failure model.

Establishment of Reduplicated Model of Fulminant Liver Failure and Research on Its Treatment

Efficacy of Fluidized Bed Bioartificial Liver in Treating Fulminant Hepatic Failure in Pigs: A Metabolomics Study

A new style of dimethylnitrosamine induced fulminant hepatitis in mice.

Intraperitoneal administration of fetuin-A attenuates D-galactosamine/lipopolysaccharide-induced liver failure in mouse

[Liver Fibrosis Inhibits Lethal Injury Through D-galactosamine/lipopolysaccharide-induced Necroptosis].

A Novel Acute Lethal Liver Injury Mouse Model with Visualization of NF-κB Activity for Treatment of Severe Acute Liver Injury.

The Protective Effects of a Modified Xiaohua Funing Decoction against Acute Liver Failure in Mice Induced by D-Gal and LPS

Establishment of Lipopolysaccharide Inducing Mouse Acute Liver Iniurv and Lethal Model

Employment of digital gene expression profiling to identify potential pathogenic and therapeutic targets of fulminant hepatic failure

Establishment of an Acute Hepatic Failure Model in Pigs

Establishment of pig models of acute hepatic failure induced by drugs